Search

Researchers from Peking Union Medical College Hospital conducted studies on HIV/AIDS patients coinfected with Hepatitis B Virus (HBV) to understand the immunological characteristics associated with combination antiretroviral therapy (cART). They found that patients with HBsAg clearance after cART initiation exhibited distinct immune phenotypes compared to those who retained HBsAg. The decline in HBsAg levels during cART involved significant alterations in CD4+ and CD8+ T cells phenotypes, providing insights into a potential functional HBV cure. This research sheds light on the complex interactions between HIV and HBV infections and the immune response in coinfected individuals. [Extracted from the article]

A study conducted at the University of Hong Kong explored the long-term efficacy of small interfering RNA (siRNA) on hepatitis B surface antigen (HBsAg) suppression in patients with chronic hepatitis B (CHB) infection. The research followed participants who received siRNA treatments, such as ARC-520 or JNJ-3989, in combination with nucleoside analogue (NUC) for an average duration of 52.5 months. Results showed that short-duration siRNA treatment could suppress HBsAg expression with a prolonged effect for up to 6 years in some participants. The study concluded that siRNA treatment led to a faster decline in HBsAg levels compared to placebo recipients, with some participants achieving HBsAg seroclearance or lower levels at last follow-up. [Extracted from the article]

A study conducted by Fujian Medical University in Fuzhou, China, examined the efficacy of different treatment strategies using pegylated interferon (PEG-IFN) for achieving sustained clearance of hepatitis B surface antigen (HBsAg) in patients with chronic hepatitis B (CHB). The study analyzed 53 studies involving 9,338 CHB patients and found that the annual rates of HBsAg clearance and seroconversion after PEG-IFN withdrawal were 6.9% and 4.7%, respectively. The study also identified factors such as HBsAg quantification, hepatitis B e antigen status, and PEG-IFN treatment protocols as sources of heterogeneity. The researchers concluded that combining PEG-IFN with tenofovir may be the most effective approach for achieving sustained HBsAg seroconversion. [Extracted from the article]

A recent study conducted by researchers from the University of Hong Kong has found that cigarette smoking is associated with a lower chance of hepatitis B surface antigen (HBsAg) seroclearance and altered host immunity in patients with chronic hepatitis B (CHB) infection. The study analyzed data from 7833 antiviral-treated CHB subjects and performed phenotypic analysis of peripheral blood mononuclear cells (PBMCs) from 27 CHB-infected patients. The findings showed that smoking was linked to a decreased probability of HBsAg seroclearance, increased programmed death-1 (PD-1) expression on lymphocytes, and impaired effector functions of HBV-specific T cells in CHB. [Extracted from the article]

A researcher from the Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute in India has described a case of a false reactive result for hepatitis B surface antigen (HBsAg) due to dislodged gel from a Vacutainer tube. The study highlights the importance of preanalytical variables in laboratory test results and the need for repeat testing from a different sample in case of low readings. The researchers emphasize the impact of such errors on patients' mindset, treatment outcomes, and blood donation. They suggest the development of guidelines to prevent such errors in the future. [Extracted from the article]

A study conducted by researchers at the First Affiliated Hospital of Xi'an Jiaotong University in China has found that pegylated interferon alpha-2b treatment can effectively achieve a high rate of functional cure in postpartum women with chronic hepatitis B virus (HBV) infection. The study included 150 HBeAg-negative postpartum women, with 47 receiving pegylated interferon alpha-2b treatment and 103 not receiving it. The results showed that the treatment group had higher rates of HBsAg loss and seroconversion compared to the non-treatment group. Factors such as baseline HBsAg levels, HBsAg at week 24, HBsAg decline at week 24, and postpartum flare were significantly associated with HBsAg loss. The study concluded that pegylated interferon alpha-2b treatment is a safe and effective option for postpartum women with chronic HBV infection, particularly for those with low baseline HBsAg levels and experiencing postpartum flare. [Extracted from the article]

A recent study conducted by researchers at Jilin University in Changchun, People's Republic of China, has developed a new method for detecting hepatitis B surface antigen (HBsAg) with high accuracy. The researchers utilized a label-free plasmonic biosensing method combined with supervised deep learning using neural networks. This approach significantly improved the accuracy of detection and reduced the limit of detection, resulting in more precise molecular detection tools for point-of-care applications. The findings offer a promising avenue for improving the diagnosis and treatment of hepatitis B virus (HBV) infection. [Extracted from the article]

Researchers at the Pasteur Institute of Iran have conducted a study on the purification of recombinant hepatitis B surface antigen (rHBsAg) from Pichia pastoris industrial feedstock. They used Capto adhere, a strong ion exchanger with multimodal functionality, and optimized various parameters using the design of experiments (DOE) approach. The study found that Capto adhere was effective in purifying rHBsAg, achieving a binding capacity higher than other reported resins. The researchers concluded that Capto adhere could be considered a good candidate for efficient purification of rHBsAg in downstream processing. [Extracted from the article]

A recent study conducted in Botswana examined the impact of hepatitis D virus (HDV) infection on the development of unique hepatitis B virus (HBV) mutations among people living with HIV. The study analyzed HBV sequences from participants in the Botswana Combination Prevention Project and identified 182 common mutations between the HIV/HBV-positive and HIV/HBV/HDV-positive cohorts. Only three mutations were classified as deleterious in the HIV/HBV/HDV cohort, while four mutations were classified as deleterious in the HIV/HBV cohort. The study suggests further investigation into the functional characterization of these mutations to determine their effect on HDV. [Extracted from the article]

A study conducted by researchers at Kaohsiung Medical University in Taiwan explored the factors contributing to the loss of hepatitis B surface antigen (HBsAg) in patients with chronic hepatitis B (CHB) and low viral load. The study included 80 patients with CHB, with 17 of them experiencing HBsAg loss during the follow-up period. The factors associated with HBsAg loss were found to be younger age, prior treatment with nucleoside/nucleotide analogues (NAs), and current treatment with NAs. The study also noted that some patients experienced HBsAg loss during NAs therapy. This research provides valuable insights into the management of CHB in patients with low viral load. [Extracted from the article]

A recent study conducted at Erasmus University Medical Center in Rotterdam, Netherlands, explored the gene profiles of B cells in patients with chronic hepatitis B virus (HBV) infection. The researchers found a distinctive B-cell activation gene signature in the blood and liver of patients with immune active chronic HBV, characterized by an upregulation of immune-related genes. This suggests that B-cell gene profiles may reflect responsiveness to HBV infection and could be relevant for clinical studies evaluating treatment strategies for HBV. The role of B cells in controlling chronic HBV infection is still not well established. [Extracted from the article]

A study conducted at Henan Province People's Hospital in Zhengzhou, China, explored the efficacy and safety of pegylated interferon alpha-2b (PegIFN alpha-2b) therapy for inactive hepatitis B surface antigen (HBsAg) carriers. The study enrolled 40 participants who were randomized into two groups: one receiving PegIFN alpha-2b monotherapy and the other receiving PegIFN alpha-2b-based immunotherapy. The primary endpoint was the HBsAg loss rate at 68 weeks, and the study found that both treatment approaches resulted in similar HBsAg loss rates. The therapies were well-tolerated, and the adverse events were common and mild. The study suggests that PegIFN alpha-2b-based therapy could be an effective treatment option for inactive HBsAg carriers. [Extracted from the article]

A recent study conducted by researchers at Central South University in Changsha, China, aimed to understand the clinical and virological characteristics of chronic hepatitis B virus (HBV) infection in pediatric patients who simultaneously test positive for both hepatitis B surface antigen (HBsAg) and antibody against HBsAg (anti-HBs). The study found that 22.8% of the 413 enrolled subjects had coexistent HBsAg and anti-HBs. Children with this specific serological pattern were typically younger and showed signs of early liver impairment and lower HBV replication activity. The study provides valuable insights into the prevalence and characteristics of this specific serological pattern in pediatric patients with chronic HBV infection. [Extracted from the article]

A study conducted by researchers at Juntendo University in Shizuoka, Japan, has found that measuring O-glycosylated middle hepatitis B surface antigen (HBsAg glycan isomer, HBsAgGi) can help predict the seroclearance of hepatitis B surface antigen (HBsAg) in patients with chronic hepatitis B (CHB). The study analyzed 232 treatment-naïve patients with CHB genotype C and found that patients with low HBsAgGi levels had a significantly higher probability of HBsAg seroclearance compared to those with high HBsAgGi levels. The researchers concluded that measuring HBsAgGi levels could be a novel predictor of HBsAg seroclearance. [Extracted from the article]

A recent study conducted at the University of Bern in Switzerland has provided new insights into HIV/AIDS. The research focused on the long-term trajectories of hepatitis B virus (HBV) RNA and hepatitis B core-related antigen (HBcrAg) in individuals with and without hepatitis B surface antigen (HBsAg) loss during tenofovir therapy. The study found that HBV RNA suppression preceded undetectable quantitative HBsAg levels and had high sensitivity but low specificity for HBsAg loss in individuals with HIV. The researchers suggest that combining HBV RNA and HBcrAg decline during the early stages of tenofovir therapy could improve predictions of HBsAg loss in future HBV drug trials. [Extracted from the article]

Researchers from Sun Yat-sen University in Zhuhai, China have published a new study on hepatitis. The study focuses on the use of a technique called laser-assisted lateral flow assay (LFA) for quantitative detection of hepatitis B surface antigen (HBsAg). The researchers found that the laser-assisted LFA produced similar results to the gold standard technique, enzyme-linked immunosorbent assay. This research provides valuable insights into the potential of LFA for quantitative analysis in the field of hepatitis detection. [Extracted from the article]

This document provides information about a clinical trial for HRS-5635 Injection, a drug being tested for the treatment of chronic hepatitis B. The trial is being conducted in China and aims to evaluate the efficacy and safety of HRS-5635 injection alone or in combination with other agents. The study will assess changes in serum hepatitis B surface antigen levels and the proportion of subjects with negative antigen levels. The trial is expected to enroll 150 participants and be completed by September 2026. The responsible party for the trial is Fujian Shengdi Pharmaceutical Co., Ltd. [Extracted from the article]

A recent study conducted by researchers at the University of Southern Queensland explores the use of virus-like particles (VLPs) as a potential vaccine for hepatitis B virus (HBV) and Streptococcus pyogenes (Strep A). VLPs are noninfective and safe, and they have been used successfully in vaccines for other viruses. The researchers developed a vaccine by expressing a bacterial epitope from Strep A on the surface of a recombinant VLP. The vaccine, called VLP-p17, induced a strong immune response in mice, suggesting its potential as a vaccine candidate. This research could contribute to the development of vaccines for HBV and Strep A, particularly in resource-poor communities where these infections are prevalent. [Extracted from the article]

Glaxosmithkline Biologicals SA has been issued a patent for a hepatitis B immunization regimen and compositions. This patent aims to address the global public health problem of hepatitis B virus (HBV) infection, which affects millions of people worldwide. The current treatment strategy for chronic hepatitis B focuses on long-term suppression of HBV DNA replication, but achieving a functional cure is rare. The patent discusses an immunogenic composition that includes various vectors and antigens to stimulate an immune response against the hepatitis B virus. The invention aims to provide a treatment that can clear hepatitis B surface antigen (HBsAg) and allow patients to discontinue antiviral therapy without relapse. [Extracted from the article]

This document discusses the requirement for blood establishments to test donations of human blood and blood components for hepatitis B virus using approved screening tests. One such test is the hepatitis B surface antigen (HBsAg) test. The document provides information on how to submit comments on the guidance and includes contact information for further questions. The document also includes keywords related to FDA, biotechnology, immunology, and hepatitis B. [Extracted from the article]

A recent study conducted by Gilead Sciences Inc. has focused on the development of a therapeutic vaccine for Hepatitis B Virus (HBV). The researchers used non-replicating arenavirus vectors to induce CD8 T cell-mediated clearance of infected hepatocytes and anti-hepatitis B surface antigen (HBsAg) antibodies. The study found that alternating immunizations with these vectors resulted in high-magnitude HBV T cell responses and high anti-HBs titers. The researchers concluded that these vectors could potentially become a central component of cure regimens for HBV. [Extracted from the article]

A recent study conducted at the University of Duisburg-Essen in Germany aimed to identify factors associated with hepatitis B surface antigen (HBsAg) seroconversion in patients with chronic hepatitis B virus (HBV) infection. The study found that antiviral therapy was associated with a lower chance of seroconversion, while male gender, low viral load, and low inflammatory activity were positively correlated with seroconversion. The researchers concluded that treatment-naive male patients with low viral load and inflammatory activity have the best chance of achieving seroconversion, and antiviral therapy should not be performed in this patient group in the absence of cirrhosis. [Extracted from the article]

A recent study conducted by researchers at Central South University examined the association between the coexistence of hepatitis B surface antigen (HBsAg) and hepatitis B surface antibody (HBsAb) and clinical treatment outcomes in children with chronic hepatitis B (CHB). The study included 372 treatment-naive CHB children and found that those who tested positive for both HBsAg and HBsAb had a higher likelihood of favorable outcomes after antiviral treatment. The researchers concluded that children with HBsAb-positive CHB should be actively treated to achieve functional cure. This study provides valuable insights into the management of chronic hepatitis B in children. [Extracted from the article]

A new report from Universitas Hasanuddin discusses research findings on the risk factors for intrauterine transmission of hepatitis B virus (HBV) in HBsAg-positive pregnant women. The study found that a high maternal viral load and positive HBeAg were risk factors for intrauterine transmission, while negative HBeAg still had the possibility of transmission. The study also highlighted the role of placental barrier and viral factors in transmission. These findings contribute to a better understanding of the transmission of HBV from mother to child and may inform prevention strategies. [Extracted from the article]

A study conducted by Erlanger Health System in Chattanooga, Tennessee, examines the evaluation and treatment of infants exposed to nongenital herpes simplex virus-2 (HSV-2) through pregnant individuals. The study highlights the risks of infant morbidity and mortality associated with primary nongenital HSV infections in pregnant individuals and the need for further investigation into the evaluation and treatment of these infants. The study also provides information on the transmission and manifestations of HSV infections in infants. The article calls for more research to develop guidelines for the evaluation and treatment of infants born to pregnant individuals with primary nongenital HSV infections. [Extracted from the article]

A study conducted by Erlanger Health System in Chattanooga, Tennessee, examines the transmission of herpes simplex virus (HSV) from pregnant individuals to their infants. The study reveals that pregnant individuals with primary nongenital HSV infections can pass the virus to their fetus or infant, resulting in significant health issues or even death. The research emphasizes the necessity for additional studies on the assessment and treatment of infants born to pregnant individuals with primary nongenital HSV infections. It also underscores the importance of considering the risk of infant HSV infection when pregnant individuals present with primary versus recurrent nongenital HSV infections. The study highlights the seriousness of infant HSV infection, which can lead to severe neurological complications. The highest risk of transmission occurs when an HSV-positive pregnant person has active genital lesions during delivery. Pregnant individuals who experience their first genital HSV outbreak during pregnancy have a 5% chance of transmitting the virus to their baby. While there are specific recommendations for evaluating and treating infants born to pregnant individuals with active genital lesions, there are currently no guidelines for infants born to pregnant individuals with primary nongenital HSV outbreaks. Further research is necessary to develop guidelines for this particular population. [Extracted from the article]

A recent study conducted by researchers at the Karlsruhe Institute of Technology (KIT) in Germany has outlined findings on gene therapy. The study focused on the development of analytical methods for the absolute quantification of Hepatitis B core Antigen (HBcAg) virus-like particles (VLPs) and bound nucleic acids. The researchers investigated a silica spin column-based extraction procedure and a reversed-phase high-performance liquid chromatography (RP-HPLC) method for quantifying the proteins and nucleic acids. These methods are crucial for the effective development of gene delivery vehicles using HBcAg VLPs. [Extracted from the article]

Researchers from Toho University in Tokyo, Japan have discovered a case of hepatitis B virus (HBV)-related membranous nephropathy (MN) in an inactive carrier of positive hepatitis B surface antigen (HBs antigen) with undetectable HBV-DNA under anti-viral treatment. The patient, a 52-year-old man, developed nephrotic syndrome and a renal biopsy revealed advanced MN with crescentic formation. Immunofluorescence studies showed granular IgG deposition and HBs antigen-positivity along the capillaries. The researchers concluded that HBV-related kidney disease should be considered even in patients with an inactive HBV carrier status under treatment. This research has been peer-reviewed and published in Internal Medicine. [Extracted from the article]

A study conducted in Botswana aimed to determine the loss of hepatitis B surface antigen (HBsAg) among individuals with chronic hepatitis B (CHB) infections and HIV. The study found that 7.1% of participants with negative HBeAg and negative IgM serologies experienced HBsAg loss. The loss of HBsAg was independent of factors such as HIV viral load, CD4+ cell count, age, and sex. The researchers suggest further studies to explore HBsAg loss in mono-infected patients and the correlation between HBeAg status and HBsAg loss. [Extracted from the article]

A recent study conducted by researchers at Capital Medical University in Beijing, China, aimed to develop a prediction model for the clearance of hepatitis B surface antigen (HBsAg) in patients with chronic hepatitis B (CHB) before interferon therapy. The study enrolled 131 patients with CHB who underwent interferon therapy and found that certain gene polymorphisms and laboratory results were independently associated with HBsAg clearance. The model that included specific gene markers and baseline HBsAg levels had the best predictive performance for HBsAg clearance. The researchers concluded that pre-treatment laboratory results and gene polymorphisms may have a good predictive value for HBsAg clearance after interferon therapy in patients with CHB. [Extracted from the article]

A recent study conducted by researchers at the University of Belgrade in Serbia has provided new insights into the clinical implications of hepatitis B surface antigen (HBsAg) isoforms. The study found that these isoforms have various biological functions during HBV infection and may play a role in different liver phases and clinical manifestations. The researchers suggest that quantifying HBsAg isoforms could serve as a useful non-invasive biomarker for assessing chronically infected patients. This research has the potential to contribute to the development of new therapeutic approaches and improve the evaluation and prediction of chronic infection phases. [Extracted from the article]

A recent study conducted at Hazara University aimed to clone and express the hepatitis B surface antigen gene (HBsAg) in Escherichia coli (E. coli) in order to develop potential local therapeutics for combating Hepatitis B virus (HBV) infection in the Pakistani community. Blood serum samples from hepatitis B-infected patients were collected, and the HBsAg gene was cloned into the pET20b expression vector and transformed into E. coli BL21 (DE3). The expression of HBsAg protein was confirmed through various analyses. The study concluded that the expressed protein clones could be further developed as a local recombinant DNA vaccine to prevent hepatitis B viral infection in the local community. [Extracted from the article]

A study conducted in Baku, Azerbaijan, explored the use of hepatitis B surface antigen (HBsAg) quantification as a noninvasive biomarker for monitoring hepatitis B virus (HBV) infection. The researchers evaluated HBsAg levels in serum samples from 66 patients with chronic hepatitis B (CHB) and correlated them with HBV DNA levels and liver histopathology. The study found a positive correlation between HBsAg levels and the severity of fibrosis scores and HBV DNA levels, suggesting that HBsAg quantification could be a useful diagnostic test for predicting fibrosis severity and HBV DNA level. This research provides valuable insights into the monitoring and diagnosis of CHB. [Extracted from the article]

A recent study conducted by researchers at China Medical University in Taichung, Taiwan, has found that hepatic events can occur after discontinuing antiviral therapy for hepatitis. The study compared hepatitis flares and hepatic decompensation in non-cirrhotic hepatitis B e antigen-negative patients who had discontinued either tenofovir disoproxil fumarate (TDF) or entecavir (ETV). The results showed that the cumulative rates of hepatitis flare at 6 months after discontinuing ETV and TDF were 2% and 19%, respectively, while the rates of hepatic decompensation were 0% and 7%. Factors such as higher alanine aminotransferase levels, rapid rebound of HBV DNA, and discontinuation of TDF were found to be independently associated with hepatitis flares. Older age and off-therapy dynamic change in HBV DNA were independently associated with hepatic decompensation. This study provides valuable insights into the factors associated with hepatic events after discontinuing antiviral therapy in non-cirrhotic hepatitis B e antigen-negative patients. [Extracted from the article]

A report from Duke University School of Medicine discusses research on HIV/AIDS and the need for an effective vaccine. The researchers developed a conjugate vaccine regimen using a modified vaccinia virus to express both HIV-1 envelope and hepatitis B virus surface antigen. They found that the conjugate vaccine stimulated T cell help and modified antibody responses in rhesus macaques, but further research is needed to improve the durability and efficacy of next-generation HIV vaccines. The full report can be accessed for free through the provided link. [Extracted from the article]

A recent study conducted by investigators from the University of Hong Kong has found that low levels of plasma interferon-gamma-inducible-protein 10 (IP-10) may be a predictive factor for spontaneous hepatitis B surface antigen (HBsAg) seroclearance in patients with chronic hepatitis B (CHB). The study analyzed plasma samples from 100 CHB patients and found that plasma IP-10 levels were significantly lower in patients who experienced HBsAg seroclearance compared to those who remained HBsAg positive. The researchers suggest that measuring IP-10 levels could be a useful tool in predicting HBsAg seroclearance, particularly in patients with low HBsAg levels. This research has been peer-reviewed and published in the Journal of Gastroenterology and Hepatology. [Extracted from the article]

For more information on this research see: The Efficacy and Safety of Pegylated Interferon α-2b-based Immunotherapy for Inactive Hepatitis B Surface Antigen Carriers. Keywords: Zhengzhou; People's Republic of China; Asia; Antigens; Antivirals; Biological Factors; Cytokines; Digestive System Diseases and Conditions; Drugs and Therapies; Gastroenterology; Health and Medicine; Hepatitis; Hepatitis B Antigens; Hepatitis B Surface Antigens; Immunology; Immunotherapy; Infectious Diseases and Conditions; Intercellular Signaling Peptides and Proteins; Interferon Type I; Interferon-alpha; Interferons; Liver Diseases and Conditions; Peginterferon Alfa-2b Therapy; Peptides; Pharmaceuticals; Proteins; Surface Antigens EN Zhengzhou People's Republic of China Asia Antigens Antivirals Biological Factors Cytokines Digestive System Diseases and Conditions Drugs and Therapies Gastroenterology Health and Medicine Hepatitis Hepatitis B Antigens Hepatitis B Surface Antigens Immunology Immunotherapy Infectious Diseases and Conditions Intercellular Signaling Peptides and Proteins Interferon Type I Interferon-alpha Interferons Liver Diseases and Conditions Peginterferon Alfa-2b Therapy Peptides Pharmaceuticals Proteins Surface Antigens 1480 1480 1 11/06/23 20231110 NES 231110 2023 NOV 6 (NewsRx) -- By a News Reporter-Staff News Editor at Hepatitis Weekly -- Investigators discuss new findings in Liver Diseases and Conditions - Hepatitis. [Extracted from the article]

Keywords: Aminotransferase; Antigens; Biological Factors; Biomarkers; Chronic Hepatitis; Chronic Hepatitis B Virus; DNA Viruses; Diagnostics and Screening; Digestive System Diseases and Conditions; Enzymes and Coenzymes; Gastroenterology; Genetics; Health and Medicine; Hepadnaviridae; Hepadnaviridae Infections; Hepatitis; Hepatitis B Antigens; Hepatitis B Surface Antigens; Hepatitis B Virus; Hepatology; Immunology; Infectious Diseases and Conditions; Liver Diseases and Conditions; Orthohepadnavirus; Risk and Prevention; Surface Antigens; Viral; Virology EN Aminotransferase Antigens Biological Factors Biomarkers Chronic Hepatitis Chronic Hepatitis B Virus DNA Viruses Diagnostics and Screening Digestive System Diseases and Conditions Enzymes and Coenzymes Gastroenterology Genetics Health and Medicine Hepadnaviridae Hepadnaviridae Infections Hepatitis Hepatitis B Antigens Hepatitis B Surface Antigens Hepatitis B Virus Hepatology Immunology Infectious Diseases and Conditions Liver Diseases and Conditions Orthohepadnavirus Risk and Prevention Surface Antigens Viral Virology 810 810 1 10/30/23 20231030 NES 231030 2023 OCT 30 (NewsRx) -- By a News Reporter-Staff News Editor at Hepatitis Weekly -- Research findings on chronic hepatitis B virus are discussed in a new report. For more information on this research see: Does Hepatitis B Virus DNA Forecast Chronic Hepatitis in Hepatitis B Surface Antigen-positive Patients?. [Extracted from the article]

For more information on this research see: Transplanting Hepatitis B Surface Antigen-positive Livers In the United States: Outcomes and Opportunities. Keywords: Houston; State:Texas; United States; North and Central America; Antigens; Biological Factors; DNA Viruses; Digestive System Diseases and Conditions; Gastroenterology; Health and Medicine; Hepadnaviridae; Hepatitis; Hepatitis B Antigens; Hepatitis B Surface Antigens; Hepatitis B Virus; Immunology; Infectious Diseases and Conditions; Liver Diseases and Conditions; Orthohepadnavirus; Risk and Prevention; Surface Antigens EN Houston State:Texas United States North and Central America Antigens Biological Factors DNA Viruses Digestive System Diseases and Conditions Gastroenterology Health and Medicine Hepadnaviridae Hepatitis Hepatitis B Antigens Hepatitis B Surface Antigens Hepatitis B Virus Immunology Infectious Diseases and Conditions Liver Diseases and Conditions Orthohepadnavirus Risk and Prevention Surface Antigens 478 478 1 10/16/23 20231016 NES 231016 2023 OCT 16 (NewsRx) -- By a News Reporter-Staff News Editor at Hepatitis Weekly -- Current study results on DNA Viruses - Hepatitis B Virus have been published. [Extracted from the article]

Keywords: Antibodies; Asia; Biological Factors; Blood Proteins; China; DNA Viruses; Digestive System Diseases and Conditions; Gastroenterology; Health and Medicine; Hepadnaviridae; Hepatitis; Hepatitis B Antigens; Hepatitis B Surface Antigens; Hepatitis B Virus; Immunization; Immunoglobulins; Immunology; Infectious Diseases and Conditions; Liver Diseases and Conditions; Orthohepadnavirus; Proteins; Public Health; Risk and Prevention; Surface Antigens; Vaccination EN Antibodies Asia Biological Factors Blood Proteins China DNA Viruses Digestive System Diseases and Conditions Gastroenterology Health and Medicine Hepadnaviridae Hepatitis Hepatitis B Antigens Hepatitis B Surface Antigens Hepatitis B Virus Immunization Immunoglobulins Immunology Infectious Diseases and Conditions Liver Diseases and Conditions Orthohepadnavirus Proteins Public Health Risk and Prevention Surface Antigens Vaccination 843 843 1 10/09/23 20231009 NES 231009 2023 OCT 9 (NewsRx) -- By a News Reporter-Staff News Editor at Hepatitis Weekly -- Current study results on hepatitis B virus have been published. Antibodies, Asia, Biological Factors, Blood Proteins, China, DNA Viruses, Digestive System Diseases and Conditions, Gastroenterology, Health and Medicine, Hepadnaviridae, Hepatitis, Hepatitis B Antigens, Hepatitis B Surface Antigens, Hepatitis B Virus, Immunization, Immunoglobulins, Immunology, Infectious Diseases and Conditions, Liver Diseases and Conditions, Orthohepadnavirus, Proteins, Public Health, Risk and Prevention, Surface Antigens, Vaccination. [Extracted from the article]